Gene therapy for HIV infection

Drugs of Today

Volumn 32, Issue 3, 1996, Pages 209-224

  Bunnell, Bruce A ^a   Morgan, Richard A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0029945842     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Anderson, W.F. Human gene therapy. Science 1992, 256: 808-13.
2. Baltimore, D. Intracellular immunization. Nature 1988, 335:395.
3. Sullenger, B.A., Gallardo, H.F., Ungers, G.E. et al. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990, 63: 601-8.
4. Sullenger, B.A., Gallardo, H.F., Ungers, G.E. et al. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991, 65: 6811-6.
5. Lee, S.W., Gallardo, H.R, Gilboa, E. etal. Inhibition of human immunodeficiency virus in human T cells by a potent rev response element decoy consisting of the 13-nucleotide minimal Revbinding domain. J Virol 1994, 68: 8254-64.
6. Lisziewicz, J., Rappaport, J., Dhar, R. Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. New Biol 1991, 3: 82-9.
7. Lisziewicz, J., Sun, D., Smythe, J. et al. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric tat activation response RNA decoy as a strategy for gene therapy for AIDS. Proc Natl Acad Sci USA 1993, 90: 8000-4.
8. Lisziewicz, J., Sun, D., Lisziewicz, A. et al. Antitat gene therapy: A candidate for late-stage AIDS patients. Gene Ther 1995, 2: 218-22.
9. Kinchington, D., Galpin, S., Jaroszewski, J. et al. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antivir Res 1992, 17: 53-62.
10. Morvan, F., Porumb, H., Degols, G. et al. Comparative evaluation of seven oligonucleotide analogues as potential antisense agents. J Med Chem 1993 36: 280-7.
11. Lisziewicz, J., Sun, D., Klotman, M. et al. Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: An in vitro model for treatment. Proc Natl Acad Sci USA 1992, 89: 11209-13.
12. Lisziewicz, J., Sun, D., Metelev, V. et al. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sci USA 1993, 90: 3860-4.
13. Bordier, B., Helena, C., Barr, P.J. et al. In vitro effect of antisense oligonucleotides on human immunodeficiency virus type 1 reverse transcription. Nucleic Acids Res 1992, 20: 5999-6006.
14. Agrawal, S., Tang, J.Y. GEM 91 - An antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev 1992, 2: 261-6.
15. Rhodes, A., James, W. Inhibition of heterologous strains of HIV by antisense RNA. AIDS 1991, 5: 145-51.
16. Sczakiel, G., Pawlita, M. Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA. J Virol 1991, 65: 468-72.
17. Rhodes, A., James, W. Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. J Gen Virol 1990, 71: 1965-74.
18. Joshi, S., Van Brunschot, A., Asad, S. et al. Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression. J Virol 1991, 65: 5524-30.
19. Rittner, K., Sczakiel, J. Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucleic Acids Res 1991, 19: 1421.
20. Sczakiel G, Oppenlander M, Rittner K. et al. Tat-and rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1:A temporal analysis. J Virol 1992, 66: 5576-81.
21. Chuah, M.K.L., Vandendnessche, T., Chang, H-K. et al. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Hum Gene Ther 1994, 5: 1467-75.
22. Rossi, J.J., Elkins, D., Zaia, J.A. et al. Ribozymes as anti-HIV-1 therapeutic agents: Principles, applications, and problems. AIDS Res Hum Retrov 1992, 8: 183-9.
23. Sarver, N., Cantin, E.M., Chang, P.S. et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990, 247: 1222-5.
24. Weerasinghe, M., Liem, S.E., Asad, S. et al. Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 1991, 65: 5531-4.
25. Dropulic, B., Lin, N.H., Martin, M.A. et al. Functional characterization of a U5 ribozyme: Intracellular suppression of human immunodeficiency virus type 1 expression. J Virol 1992, 66: 1432-41.
26. Wong-Staal, F., Yu, M., Yamada, O. et al. Development of ribozyme gene therapy against HIV. J Cell Biochem 1994, Suppl. 18A: 221.
27. Yamada, O., Yu, M., Yee, J.K. et al. Intracellular immunization of human cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther 1994, 1: 38-45.
28. Leavitt, M.C., Yu, M., Yamada, O. et al. Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 1994, 5: 1115-20.
29. Chen, C.J., Banerjea, A.C., Harrison, G.G. et al. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res 1992, 20: 4581-9.
30. Sullenger, B.A., Cech, T.R. Tetheringribozymes to a retroviral packaging signal for destruction of viral RNA. Science 1993, 262: 1566-9.
31. Warner, J.F., Anderson, C.G., Laube, L. et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retrov 1991, 7: 645-5.
32. Jolly, D., Chada, S., Townsend, K. et al. CTL cross reactivity between HIV strains. AIDS Res Hum Retrov 1992, 8: 1369-71.
33. Lu, S., Santoro, J.S., Fuller, D.H. et al. Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody-responses in mice. Virology 1995, 209: 147-54.
34. Marasco, W.A., Haseltine, W.A., Chen, S.Y. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp 120 single-chain antibody. Proc Natl Acad Sci USA 1993, 90: 7889-93.
35. Duan, L., Bagasra, O., Laughlin, M.A. et al. Potent inhibition of human immunodeficiency virus type 1 by an intracellular anti-rev singlechain antibody. Proc Natl Acad Sci USA 1994, 91: 5075-9.
36. Mhashilkar, A.M., Bagley, J., Chen, S.Y. et al. Inhibition of HIV-1 tat-mediated LTR transactivation and HIV-1 infection by anti-tat single chain intrabodies. EMBO J 1995, 14: 1542-51.
37. Herskowitz, I. Functional inactivation of genes by dominant negative mutations. Nature 1987, 329: 219-22.
38. Feinberg, M.B., Trono, D. Intracellular immunization: Trans-dominant mutants of HIV gene products as tools for the study and interruption of viral replication. AIDS Res Hum Retrov 1992, 8: 1013-22.
39. Malim, M.H., Bohnlein, S., Hauber, J. et al. Functional dissection of HIV-1 rev transactivator derivation of a trans-dominant repressor of rev function. Cell 1989, 58: 205-14.
40. Malim, M.H., McCarn, D.F., Tiley, L.S. et al. Mutational definition of the human immunodeficiency virus type 1 rev activation domain. J Virol 1991, 65: 4248-54.
41. Bahner, I., Zhou, C., Yu, X. et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993, 67: 3199-207.
42. Woffendin, C., Yang, Z-Y., Udaykumar, R. et al. Nonviral and viral delivery of human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci USA 1994, 91: 11581-5.
43. Esaich, S., Kalfoglou, C., Plavec, I. et al. RevM10-mediated inhibition of HIV-1 replication in chronically infected T-cells. Hum Gene Ther 1995, 6:625-34.
44. Ragheb, J.A., Bressler, P., Daucher, M. et al. Analysis of trans-dominant mutants of the HIV-1 rev protein for their ability to inhibit rev function, HIV-1 replication, and their use as anti-HIV gene therapeutics. AIDS Res Hum Retrov 1995, 11: 1343-53.
45. Chuah, M.K.L., VandenDriessche, T., Chang, H. et al. Inhibition of human immundeficiency virus type-1 by retroviral vectors expressing of antisense TAR. Hum Gene Ther 1994, 5: 1467- 75.
46. VandenDriessche, T., Chuah, M.K.L., Chiang, L et al. Inhibition of clinical human immunodeficiency virus type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1992, 69: 4045-52.
47. Kubota, S., Furuta, R., Maki, M. et al. Inhibition of human immunodeficiency virus type 1 rev function by a rev mutant which interferes with nuclear/nucleolar localization of rev. J Virol 1992, 66: 2510-3.
48. Modesti, N., Garcia, J., Debouck, C. et al. Transdominant tat mutants with alterations in the basic domain inhibit HIV-1 gene expression. New Biol 1991, 3: 759-68.
49. Green, M., Ishino, M., Loewenstein, P.M. Mutational analysis of HIV-1 tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 1989, 58: 215-23.
50. Liem, S.E., Ramezani, A., Li, X., Joshi, S. The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum Gene Ther 1993, 4: 625-34.
51. Aguilar-Cordova, E., Chinen, J., Donehower, L.A et al. Inhibition of HIV-1 by a double transdominant fusion gene. Gene Ther 1995, 2: 181-6.
52. Trono, D., Feinberg, M.B., Baltimore, D. HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989, 59: 113-20.
53. Yu, X., Yuan, X., Matsuda, Z. et al. The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol 1992, 66: 4966-71.
54. Lee, P.P., Linial, M.L. Inhibition of wild-type HIV-1 virus production by a matrix deficient gag mutant. Virol 1995, 208: 808-11.
55. Schwartz, S., Felber. B.K., Pavlakis, G.N. Distinct sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of rev protein. J Virol 1992, 66: 150-9.
56. Schwartz, S., Campbell, M., Nasioulas, G. et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in rev-independent gag expression. J Virol 1992, 66: 7176-82.
57. Buchschacher, G.L. Jr., Freed, E.O., Panganiban, A.T. Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum Gene Ther 1992, 3: 391-7.
58. Rill, D.R., Moen, R.C., Buschle, M. et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow trans-plantation using retrovirus-mediated gene transfer. Blood 1992, 15: 2694-700.
59. Van Beusechem, V.W., Kukler, A., Heidt, P.J. et al. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone marrow cells. Proc Natl Acad Sci USA 1992, 89: 7640-4.
60. Kohn, D.B., Weinberg, K.I., Parkman, R. et al. Gene therapy for neonates with ADA-deficient SCID by retroviral-mediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. J Cell Biochem 1994, Suppl. 18A: 238.
61. Apperly, J.F., Luskey, B.D., Williams, D.A. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: Effect of selectable marker sequences on long-term expression. Blood 1991, 78: 310-7.
62. Challita, P-M., Kohn, D.B. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994, 91: 2567-71.
63. Culver, K., Cornetta, K., Morgan, R. et al. Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Natl Acad Sci USA 1991, 88: 3155-9.
64. Culver, K.C., Morgan, R.A., Osborne, W.R. et al. In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. Hum Gene Ther 1990, 1: 399-409.
65. Rosenberg, S.A., Aebersold, P.M., Cornetta, K. et al. Gene transfer into humans: Immunotherapy of patients with advanced melanoma using tumor infiltrating lymphocytes modified by retroviral gene transduction. New Engl J Med 1990, 323: 570-8.
66. Blaese, R.M., Culver, K.W., Miller, A.D. et al. T lymphocyte-directed gene therapy for ADASCID: Initial trial results after four years. Science 1995, 270: 475-9.
67. Koup, R.A., Safrit, J.T., Cao, Y. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68: 4650-5.
68. Walker, B.D., Chakrabarti, S., Moss, B. et al. HIV-specific cytotoxic Tlymphocytes in seropsitive individuals. Nature 1987, 328: 345-8.
69. Langlade-Demoyen, P., Michel, F., Hoffenbach, A. et al. Immune recognition of AIDS virus antigens by human and murine cytotoxic T lymphocytes. J Immunol 1988, 141: 1949-57.
70. Riviere, Y., Tanneau-Slavadori, F., Regnault, A. et al. Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: Distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol 1989, 63: 2270-7.
71. Walker, B.D., Flexner, C., Paradis, T.J. et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988, 240: 64-6.
72. Hosmalin, A., Clerici, M., Houghten, R. et al. An epitope in human immunodeficiency virus type 1 reverse transcriptase recognized by both mouse and human cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1990, 87: 2344-8.
73. Culmann, B., Gomard, E., Kieny, M-P. et al. An antigen peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol 1990, 19: 2383-6.
74. McChesney, M., Tanneau, F., Regnault, A. et al. Detection of primary cytotoxic T lymphocytes specific for the envelope glycoprotein of HIV-1 by deletion of env amino-terminal signal sequence. Eur J Immunol 1990, 20: 215-20.
75. Riddell, S.R., Greenberg, P.D., Overell, R.W. et al. Phase I study of cellular adoptive immunotherapy using genetically modified CDS+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum Gene Ther 1992, 3: 319-38.
76. Lieberman, J., Fabry, J.A., Shankar, P. et al. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retrov 1995, 11: 257-72.
77. Tsubota, H., Lord, C.I., Watkins, D.I., Morimoto, C. et al. A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes. J Exp Med 1989, 169: 1421-34.
78. Miller, A.D. Retroviral vectors. Curr Top Microbiol Immunol 1992, 158: 1-24.
79. Morgan, R.A. Retroviral vectors in human gene therapy. In: Human Viruses in Gene Therapy. Vos, J-M.H. (Ed.). Academic Press: Durham, NC 1994, 77-107.
80. Mulligan, R.C. The basic science of gene therapy. Science 1993, 260: 926-32.
81. Perricaudet, M., Stratford-Perricaudet, L.D. Adenovirus-mediated in vivo gene therapy. In: Human Viruses in Gene Therapy. Vos, J-M.H. (Ed.). Academic Press: Durham, NC 1994, 1-32.
82. 1-antitrypsin gene to the lung epithelium in vivo. Science 1991, 252: 431-4.
83. Rosenfeld, M.A., Yoshimura, K., Trapnell, B. et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992, 65: 143-55.
84. Muzyczka, N. Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol 1992, 158: 97-129.
85. Samulski, R.J. Parvoviruses. In: Human Viruses in Gene Therapy. Vos, J-M.H. (Ed.). Academic Press: Durham, NC 1994, 53-76.
86. Felgner, P.L., Gadek, T.R., Holm, M. et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987, 84: 7413-7.
87. Wu, G.Y., Wilson, J.M., Shalaby, F. et al. Receptor-mediated gene delivery in vivo. Partial correction of genetic analbuminemia in Nagase rats. J Biol Chem 1991, 266: 14338-42.
88. Curiel, D.T. Gene transfer mediated by adenovirus-polylysine-DNA complexes. In: Human Viruses in Gene Therapy. Vos, J-M.H. (Ed.). Academic Press: Durham, NC 1994, 179-212.
89. Wagner, E., Zatloukal, K., Cotten, M. et al. Coupling of adenovirus to transferrin-polylysine/ DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992, 89: 6099-103.
90. Curiel, D.T., Wagner, E., Cotten, M. et al. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992, 3: 147-54.
91. Walker, R. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. Hum Gene Ther 1993, 4: 659-80.
92. Pantaleo, G., Graziosi, C.. Demarest, J.F. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362: 355-8.
93. Walker, B.D., Plata, F. Cytotoxic T lymphocytes against HIV. AIDS 1990, 4: 177-84.
94. Fauci, A.S., Schnittman, S.M., Poli, G. et al. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med 1991, 114: 678-93.
95. Kundu, S.K., Merigan, T.C. Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV-infection. Immunology 1991, 74: 567-71.
96. Carmichael, A., Jin, X., Sissons, P., Borysiewicz, L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177: 249-56.
97. Reusser, P., Riddell, S.R., Meyers, J.D., Greenberg, P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78: 1373-80.
98. Hope, T.J., Klein, N.P., Elder, M.E., Parslow, T.G. Trans-dominant inhibition of human immunodeficiency virus type 1 rev occurs through formation of inactive protein complexes. J Virol 1992, 66: 1849-55.
99. Malim, M.H., Freimuth, W.W., Liu, J. et al. Stable expression of trans-dominant rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992, 176: 1197-201.
100. Nabel, G., Fox, B.A., Post, L., Thompson, C.B., Woffendin, C. A molecular genetic intervention for AIDS - Effects of a trans-dominant negative form of rev. Hum Gene Ther 1994, 5: 79-92.
101. Vaishnav, Y.N., Wong-Staal, F. The biochemistry of AIDS. Annu Rev Biochem 1991, 60: 577-630.
102. Frankel, A.D. Activation of HIV transcription by tat. Curr Opin Genet Dev 1992, 2: 293-8.
103. Berkhout, B., Silverman, R.H., Jeang, K.T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989, 59: 273-82.
104. Cullen, B.R. Does HIV-1 tat induce a change in viral initiation rights? Cell 1993, 73: 417-20.
105. Laspia, M.F., Rice, A.P., Mathews, M.B. HIV-1 tat protein increases transcriptional initiation and stabilizes elongation. Cell 1989, 59: 283-92.
106. Morgan, R.A., Anderson, W.F. Gene therapy for AIDS. In: Advances in Molecular Biology and Targeted Treatments for AIDS. Kumar, A. (Ed.). Plenum Press: New York 1991, 301-8.
107. VandenDriessche, T., Chuah, M.K.L., Morgan, R.A. Gene therapy for acquired immune deficiency syndrome. In: AIDS Updates. DeVita, V.T., Hellman, S., Rosenberg, S.A. (Eds.) J.B. Lippincott Co.: Philadelphia 1994, 7 (4): 1-14.
108. VandenDriessche, T., Chuah, M.K.L., Chiang, L., Chang, H.K., Ensoli, B., Morgan, R.A. Inhibition of clinical HIV-1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995, 69: 4045-52.
109. Chada, S., Dejesus, C.E., Townsend, K. et al. Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J Virol 1993, 67: 3409-17.
110. Laube, L.S., Burrascano, M., De Jesus, C.E. et al. Cytotoxic Tlymphocytes (CTL) and antibody responses generated in rhesus monkeys immunized with retroviral-vector transduced fibroblasts expressing HIV-1 IIIB env/rev proteins. Hum Gene Ther 1994, 5: 853-62.
111. Warner, J.F., Anderson, G.G., Laube, L. et al. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retrov 1991, 7: 645-55.
112. Irwin, M.J., Laube, L.S., Lee, V. et al. Direct injection of recombinant retroviral vector induces human immunodefeciency virus-specific immune responses in mice and nonhuman primates. J Virol 1994, 68: 5036-44.